Published in Blood Weekly, September 11th, 2003
"Chronic graft-versus-host disease (cGVHD) is a major barrier to successful allogeneic stem cell transplantation," scientists in the United States explained. "Pentostatin has been used to treat cGVHD in a small series of pediatric patients."
J.D. Goldberg and colleagues described "the results of the first five pediatric patients receiving pentostatin for refractory cGVHD at Johns Hopkins Hospital."
"In this early experience, the authors saw considerable symptom response in their patients," they reported....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.